Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro Inc (NQ: ALZN )

2.600 -0.070 (-2.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 581,202
Open 2.740
Bid (Size) 2.570 (20)
Ask (Size) 2.650 (41)
Prev. Close 2.670
Today's Range 2.550 - 2.740
52wk Range 3.220 - 33.55
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
Alzamend Neuro Initiates Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease; Doses First Participant Group 
From Business Wire News Releases
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
Alzamend Neuro Has Contracted with Altasciences to Conduct Phase I Relative Bioavailability Study for AL001 for Alzheimer’s Disease in September 2021 
From Business Wire News Releases

Performance

YTD
-80.74%
-80.74%
1 Month
-50.66%
-50.66%
3 Month
-80.74%
-80.74%
6 Month
-80.74%
-80.74%
1 Year
-80.74%
-80.74%

More News

Read More
5 Best Penny Stocks To Buy Right Now According To Insiders
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Ault Global Holdings Reports Second Quarter 2021 Results
From Business Wire News Releases
Ault Global Holdings Announces Additional Investment in Alzamend Under Alzamend’s Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase
From Business Wire News Releases
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital P
From Business Wire News Releases
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
From Business Wire News Releases
Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate
Tags Briefs News alzheimer's treatment
From Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Tags TYRA EIGR LBPS
From Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Tags LIFE FBRX SBBP
From Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Tags Biotech Small Cap IBB
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.